Status: Recruiting
Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (LPE)
This is a Phase 2a, double-blind, placebo-controlled, crossover study evaluating the efficacy, safety, and patient-reported outcomes of KH-001 in men with lifelong premature ejaculation (LPE). Approximately 40 participants will receive KH-001 or placebo in two 4-week treatment periods separated by a washout.
Participants needed: 40
Trial details
Phase: Phase 2Age: 18-65Biological sex: MaleType: InterventionalSponsor: Kadence BioUpdated: Feb 25, 2026Locations: 1
Eligibility criteria
Male participants aged 18 to 65 years (inclusive) at the time of informed consen... [+12]
IELT >1 minute on more than 25% of attempts during the run-in period. [+16]